Susan O'Brien Selected Research

Myelodysplastic Syndromes (Myelodysplastic Syndrome)

6/2015	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
3/2015	Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
4/2014	Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
4/2014	Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure.
10/2013	Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
9/2013	Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
4/2013	Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
8/2012	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
3/2011	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
11/2010	Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susan O'Brien Research Topics

Disease

129	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2002
123	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020 - 03/2002
78	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2002
63	Philadelphia Chromosome 01/2021 - 04/2002
61	Neoplasms (Cancer) 01/2022 - 02/2002
55	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2017 - 01/2002
46	Leukemia 01/2018 - 03/2002
40	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2015 - 01/2002
20	Infections 11/2021 - 01/2002
18	Residual Neoplasm 01/2020 - 01/2003
17	Blast Crisis (Blast Phase) 01/2020 - 05/2002
16	Lymphoma (Lymphomas) 01/2019 - 02/2002
16	Hematologic Neoplasms (Hematological Malignancy) 11/2018 - 01/2002
15	Disease Progression 01/2022 - 06/2005
14	Diarrhea 01/2019 - 08/2002
12	Acute Promyelocytic Leukemia 01/2017 - 06/2002
10	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 02/2002
10	Anemia 01/2018 - 03/2002
9	Lymphocytosis 01/2020 - 09/2006
9	Primary Myelofibrosis (Myelosclerosis) 02/2017 - 09/2002
9	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 04/2014 - 06/2003
8	Hypertension (High Blood Pressure) 12/2019 - 11/2015
8	Thrombocytopenia (Thrombopenia) 01/2019 - 09/2002
8	Pathologic Complete Response 12/2018 - 06/2002
8	Neutropenia 11/2018 - 06/2003
8	Chromosome Aberrations (Chromosome Abnormalities) 07/2014 - 08/2002
7	Atrial Fibrillation 11/2021 - 01/2016
7	Nausea 09/2018 - 12/2003
7	Cytopenia 03/2017 - 11/2007
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2019 - 01/2014
6	Hemorrhage 12/2018 - 06/2009
6	Fatigue 12/2018 - 06/2003
6	B-Cell Lymphoma (Lymphoma, B Cell) 11/2016 - 02/2002
6	Splenomegaly 10/2011 - 03/2002
5	Exanthema (Rash) 01/2020 - 06/2009
5	Second Primary Neoplasms (Neoplasms, Second) 05/2019 - 03/2007
5	Leukocytosis (Pleocytosis) 01/2017 - 12/2003
5	Trisomy (Trisomies) 07/2015 - 08/2002
5	Burkitt Lymphoma (Burkitt's Lymphoma) 06/2015 - 03/2002
5	Lymphadenopathy 12/2014 - 01/2004
5	Hairy Cell Leukemia 10/2011 - 09/2002
5	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 09/2002
4	Pneumonia (Pneumonitis) 01/2019 - 01/2016
4	Hyperglycemia 01/2019 - 09/2006

Drug/Important Bio-Agent (IBA)

88	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 05/2002
48	ibrutinibIBA 01/2022 - 02/2012
48	Tyrosine Kinase InhibitorsIBA 01/2021 - 09/2003
42	Rituximab (Mabthera)FDA Link 12/2021 - 02/2002
35	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2018 - 03/2002
33	fludarabineIBA 12/2021 - 10/2002
32	Monoclonal AntibodiesIBA 11/2019 - 02/2002
28	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 01/2002
23	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 02/2012
23	Dasatinib (BMS 354825)FDA Link 01/2020 - 06/2006
18	Proteins (Proteins, Gene)FDA Link 11/2019 - 03/2002
18	Vincristine (Oncovin)FDA LinkGeneric 12/2018 - 01/2002
17	Inotuzumab OzogamicinIBA 01/2021 - 06/2013
15	nilotinib FDA Link 01/2020 - 06/2006
15	Alemtuzumab (Campath)FDA Link 08/2011 - 05/2003
14	Phosphotransferases (Kinase)IBA 06/2018 - 12/2003
14	Pharmaceutical PreparationsIBA 10/2017 - 02/2002
13	Dexamethasone (Maxidex)FDA LinkGeneric 05/2015 - 01/2002
13	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 04/2002
12	InterferonsIBA 06/2012 - 06/2003
11	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2017 - 06/2002
11	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2015 - 01/2002
10	Decitabine FDA Link 03/2015 - 08/2003
9	Biological ProductsIBA 01/2018 - 08/2002
9	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017 - 06/2002
8	Transaminases (Aminotransferases)IBA 12/2020 - 04/2012
8	Gemtuzumab (Mylotarg)FDA Link 01/2017 - 01/2002
8	Clofarabine (Clolar)FDA Link 06/2014 - 03/2003
7	BilirubinIBA 01/2020 - 04/2012
7	Hemoglobins (Hemoglobin)IBA 02/2014 - 04/2002
7	bcr-abl Fusion ProteinsIBA 01/2008 - 07/2002
6	idelalisibIBA 12/2020 - 09/2011
6	ponatinibIBA 01/2019 - 04/2015
6	Arsenic Trioxide (Trisenox)FDA Link 01/2017 - 05/2003
6	LigandsIBA 07/2015 - 04/2003
6	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2015 - 07/2008
6	NucleosidesIBA 06/2014 - 12/2003
6	Messenger RNA (mRNA)IBA 12/2011 - 02/2007
6	Alkylating AgentsIBA 07/2009 - 01/2004
5	acalabrutinibIBA 11/2021 - 01/2016
5	ofatumumab FDA Link 12/2018 - 10/2010
5	HomoharringtonineIBA 01/2017 - 04/2002
5	Biomarkers (Surrogate Marker)IBA 12/2015 - 02/2010
5	Methotrexate (Mexate)FDA LinkGeneric 02/2015 - 03/2002
5	Erythropoietin FDA Link 11/2010 - 04/2002
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2009 - 03/2002
5	TransferasesIBA 11/2007 - 03/2003
4	venetoclaxIBA 01/2018 - 12/2015
4	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2018 - 09/2011
4	Core Binding Factors (Core-Binding Factor)IBA 09/2017 - 07/2009
4	Lenalidomide (CC 5013)FDA Link 01/2016 - 11/2009

Therapy/Procedure

186	Therapeutics 01/2022 - 03/2002
57	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
14	Salvage Therapy 01/2021 - 08/2005
12	Stem Cell Transplantation 02/2018 - 09/2002
4	Transplantation 12/2016 - 05/2007